Plus Therapeutics approves 1-for-25 reverse stock split to meet Nasdaq $1.00 minimum bid price

PLUS THERAPEUTICS, INC.

Reverse split at 1-for-25, effective 12:01 a.m. ET on April 2, 2026; shares drop from ~171.6M to ~6.86M.
Action taken to increase per-share price above Nasdaq's $1.00 minimum bid requirement for continued listing.
No fractional shares issued; cash in lieu; new CUSIP 72941H806; trading symbol stays PSTV.
Broadridge acts as exchange agent; book-entry holders need no action; certificates receive instructions.
Par value unchanged at $0.001; proportional adjustments to equity awards and warrants.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

PLUS THERAPEUTICS, INC.: Amendment to Certificate of Incorporation to effect a 1-for-25 reverse stock split of common stock, approved by stockholders and Board, effective April 2, 2026 (effective 2026-04-02).

Change: charter amendment
Effective: 2026-04-02

Exact text from the filing

the Company filed a certificate of amendment to its Charter (the “Certificate of Amendment”) with the Secretary of State of the State of Delaware, to implement the 1-for-25 reverse split of its common stock (the “Reverse Stock Split”).

View on SEC.gov

74 governance changes filed in the last 30 days. Browse all governance changes →

PLUS THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001193125-26-140267

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.